Is a Nivolumab Biosimilar as Good as Opdyta?

An approved nivolumab biosimilar is held to a single regulatory standard: no clinically meaningful difference from the reference product, Opdyta, in quality, safety and clinical effect. That standard is what a family is being offered when the cheaper option appears — not a lesser drug, and not a promise about any one person's result.

Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026

Judged the way regulators judge it, yes. A biosimilar cannot be sold in India until it has shown no clinically meaningful difference from the reference product in quality, safety, immunogenicity and clinical effect. That is a defined evidentiary bar, not an opinion about one company versus another.

The question arrives in a specific moment: a nivolumab option is offered at roughly a quarter of the price, and the family has minutes to decide whether cheaper means worse. Settle it by looking at what the cheaper product had to prove first.

Two words are worth separating. A generic is a chemically identical copy of a small molecule. Nivolumab is a monoclonal antibody grown in living cells, so an identical copy is impossible for anyone — the original manufacturer included, between its own batches. A biosimilar — India's regulatory term is a similar biologic — is therefore approved not on being identical, but on evidence that its differences carry no clinical consequence.

Through a staged comparability exercise against a named reference product, under the CDSCO and Department of Biotechnology Guidelines on Similar Biologics. Each stage has to pass before the next is accepted, and the file is judged as one body of evidence.

1. 1

   A reference product is fixed

   One reference biologic, approved in India or an ICH country, is named. Every later comparison runs against it.

2. 2

   Analytical comparability

   Sequence, structure, glycosylation, charge variants, purity and potency are compared side by side — the largest part of the package.

3. 3

   Non-clinical comparability

   In-vitro receptor-binding and functional assays come first. Animal work follows only where those data leave a question open.

4. 4

   Pharmacokinetic comparison in people

   Blood levels over time must fall inside pre-set equivalence limits. A difference in exposure stops the programme.

5. 5

   Comparative clinical study

   Efficacy, safety and immunogenicity are compared in a population sensitive enough to reveal a difference.

6. 6

   Post-marketing obligations

   A pharmacovigilance and risk-management plan applies, often with a Phase IV study. Monitoring does not stop at launch.

Summarised from the CDSCO and Department of Biotechnology Guidelines on Similar Biologics. Requirements are applied case by case.

Within its approved indications, yes — equivalence is the condition of approval, not a claim made afterwards. What equivalence does not do is predict any individual result. Nivolumab benefits a proportion of patients in the cancers it is indicated for, and that proportion does not change with the brand infused.

Extrapolation is the part families most deserve explained. A biosimilar is rarely tested in every cancer the reference product covers. Once similarity is shown analytically, pharmacokinetically and in one sensitive indication, approval may be extended to the reference product's other indications where the mechanism and relevant biology are the same. For a PD-1 inhibitor the mechanism does not change between tumour types. It is a justified scientific judgement, decided case by case — not a formality.

Response rates for nivolumab vary by cancer type, line of therapy and biomarker status, and NCCN, ESMO and ASCO guidance describe them separately for each approved use. No figure from one indication reads across to another. Those numbers should come from your oncologist, against your own staging and biomarker results.

Who this page is not for

This page is not for you if nivolumab has not been raised as an option for your specific cancer, stage and biomarker profile. Checkpoint inhibitors are indicated in a defined set of situations, and most patients in India are not candidates at all. A cheaper version of a medicine that is not indicated for you is still not indicated for you.

Nivolumab, in any brand, also needs specialist caution or is unsuitable where a patient has active autoimmune disease, is on high-dose immunosuppression, has had an organ or stem-cell transplant, is pregnant or breastfeeding, or is too frail to tolerate an immune-related adverse event.

And this page is not a price quote, not a recommendation of any named brand over another, and not a route to obtain the medicine. There is no way to buy it outside a prescription-only, hospital-administered setting.

Because the development path is shorter and a second supplier has entered the market. A comparability programme costs a fraction of an original discovery and trial programme, and domestic manufacture removes import cost. The gap reflects economics, not a lower regulatory standard.

The timing in India is specific. Reported pricing when the first domestically manufactured nivolumab biosimilar launched in January 2026 placed it at roughly a quarter of the reference price, months ahead of the originator's Indian patent lapsing in May 2026. Pembrolizumab's protection is expected to begin lapsing around 2028-29. Every figure here is indicative only, as of August 2026, drawn from published manufacturer announcements and reported news — not from any hospital rate card.

Your own outlay depends on dose, cycles planned, hospital, and whether an insurance policy or a state scheme covers that brand. A per-vial comparison misleads; what matters is the cost of the full planned course under each option.

Authenticity is the real risk inside this price gap, and it should not be softened. Counterfeit checkpoint inhibitors have been reported entering the Indian market around patent and exclusivity changes, and a large price difference is exactly the environment in which a fake vial finds a buyer. Two rules follow. A checkpoint inhibitor should be dispensed and administered through the treating hospital's own pharmacy — never sourced privately, through an intermediary, or online. And ask to see the vial, the batch number and the invoice, and how cold chain was maintained. That is routine, not an accusation.

Six questions cover what matters: regulatory status, your own indication, the cost of the whole course, and how the vial reaches your arm. A good team will answer all six without hesitation.

• Which brand is being used, and is it CDSCO-approved as a similar biologic to nivolumab? The brand belongs in your file, not just the molecule.
• Is my indication approved directly, or by extrapolation? Either answer can be reasonable. You should know which applies.
• What is the cost difference across the full planned course? Cycles times dose, not the price of one vial.
• Does my insurance policy or state scheme cover this specific brand? Empanelment and formulary lists are brand-level, and they change.
• How is the vial sourced and stored, and may I see the batch number? Cold chain and provenance are fair questions on any biologic.
• What would make you change brand mid-course, and would I be told? Supply and pricing move; that plan should exist beforehand.

Related reading

• Originator vs Biosimilar Nivolumab: Opdyta vs Tishtha — the same question at brand level, in a dated table.
• When Will a Pembrolizumab (Keytruda) Biosimilar Reach India? — the same timeline, for pembrolizumab.
• What the Keytruda Patent Expiry Means for Indian Patients — why a patent date changes what a family pays.
• Counterfeit Immunotherapy Drugs in India: How to Protect Yourself — the checks behind the authenticity warning above.
• Immunotherapy Medicines Explained — the reference section this page belongs to.
• Immunotherapy at CION Cancer Clinics — how checkpoint inhibitor treatment is assessed and monitored.

Editorial information about a class of medicines — not an offer, a price list, or a recommendation to use any named product, and no comparative quality claim between manufacturers. Pricing and regulatory statements are indicative, dated to August 2026. Whether nivolumab, and which brand, applies to your treatment is a decision for your treating oncologist.